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Abstract
Quinacrine is a potent antiprion compound in cell culture models of prion disease but has failed to show efficacy in animal
bioassays and human clinical trials. Previous studies demonstrated that quinacrine inefficiently penetrates the blood-brain
barrier (BBB), which could contribute to its lack of efficacy in vivo. As quinacrine is known to be a substrate for P-
glycoprotein multi-drug resistance (MDR) transporters, we circumvented its poor BBB permeability by utilizing MDR0/0 mice
that are deficient in mdr1a and mdr1b genes. Mice treated with 40 mg/kg/day of quinacrine accumulated up to 100 mM of
quinacrine in their brains without acute toxicity. PrPSc levels in the brains of prion-inoculated MDR0/0 mice diminished upon
the initiation of quinacrine treatment. However, this reduction was transient and PrPSc levels recovered despite the
continuous administration of quinacrine. Treatment with quinacrine did not prolong the survival times of prion-inoculated,
wild-type or MDR0/0 mice compared to untreated mice. A similar phenomenon was observed in cultured differentiated
prion-infected neuroblastoma cells: PrPSc levels initially decreased after quinacrine treatment then rapidly recovered after
3 d of continuous treatment. Biochemical characterization of PrPSc that persisted in the brains of quinacrine-treated mice
had a lower conformational stability and different immunoaffinities compared to that found in the brains of untreated
controls. These physical properties were not maintained upon passage in MDR0/0 mice. From these data, we propose that
quinacrine eliminates a specific subset of PrPSc conformers, resulting in the survival of drug-resistant prion conformations.
Transient accumulation of this drug-resistant prion population provides a possible explanation for the lack of in vivo efficacy
of quinacrine and other antiprion drugs.
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Introduction
Prion diseases are a class of rare, neurodegenerative disorders
that include Creutzfeldt-Jakob disease (CJD) and kuru in humans,
BSE in cattle, and scrapie in sheep [1]. They are uniformly fatal
and follow a rapid clinical course after an extended asymptomatic
incubation period. Prion diseases are caused by an unconventional
transmissible pathogen called a prion that is devoid of nucleic acids
[2]. Prions are composed entirely of an abnormally folded
conformer of the prion protein and replicate by catalyzing the
conversion of the endogenous, cellular prion protein (PrPC) into an
aberrantly folded conformation (PrPSc) [1,3,4,5]. Although PrPSc
accumulation has been demonstrated to be the primary patho-
genic event in prion disease, the exact molecular and cellular
mechanisms of its formation and the ensuing neurodegeneration
remain largely unknown.
To date, no therapeutic agent against prion diseases has been
identified. Numerous compounds have been found to have
antiprion activity in cell culture models of prion disease, including
pentosan polysulfate, dextran sulfate, HPA-23, Congo red,
suramin, dendritic polyamines and quinacrine, among others;
for a comprehensive review, see [6]. However, none of these
compounds have been shown to be broadly effective against a
range of prion strains in animal models when administered at a
post-symptomatic clinical stage, and none have been shown to
prolong the disease course in human clinical trials.
Among the antiprion compounds, quinacrine seemed to be
the most promising for immediate application in the treatment
of prion disease because it has been used for decades as an
antimalarial drug [7]. In two independent studies, incubation of
persistently prion-infected neuroblastoma cells with quinacrine
induced the clearance of protease-resistant PrPSc [8,9]. A
subsequent study using bis-acridine compounds, which are
comprised of two acridine ring scaffolds connected by a linker,
demonstrated improved potency [10]. Despite its efficacy in cell-
culture models, quinacrine administration in vivo has not
appeared to be promising. Collins and colleagues reported that
the incubation time of mice intracerebrally inoculated with
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prions and subsequently treated with quinacrine via gavage
feeding did not differ from that of untreated mice [11]. In a
second study, intraperitoneally administered quinacrine failed to
extend the survival time of prion-infected mice [12]. In human
clinical studies, quinacrine has had mixed success. In some
patients, treatment with quinacrine transiently altered the
clinical course of disease, whereas in others it failed to improve
the clinical outcome [13] (Geschwind et al., unpublished
results).
In wild-type mice, quinacrine inefficiently penetrates the
blood-brain barrier (BBB). After an oral dose of 40 mg/kg/day,
quinacrine accumulates in the brain at concentrations of less than
1 mM ([14]; Ahn et al., manuscript in preparation; this study). The
quinacrine concentrations needed for half-maximal depletion of
PrPSc (EC50) in cell culture were reported to be ,1 mM and
,7 mM for extracellular and intracellular accumulation, respec-
tively [9,15]. Thus, the failure of quinacrine in vivo seemed likely to
result from its insufficient accumulation in the brain.
The finding that the P-glycoprotein transporter is involved in
the efflux of quinacrine across the BBB [14,16] opened another
avenue of investigation. Pgp is encoded by two genes in humans
(MDR1[ABCB1] andMDR2[ABCB4]) and three genes in rodents
(mdr1a, mdr1b and mdr2) [17]. Pgp is a member of a large family of
ATP-binding cassette (ABC) transporters, 12 of which have been
implicated in some form of drug resistance [17,18]. Pgp encoded
by MDR1 in humans, and mdr1a and mdr1b in mice, confers the
vast majority of observed multidrug resistance. Hereafter in this
paper, ‘‘Pgp’’ will refer to the proteins encoded by this class of
MDR genes (there is no current evidence that mdr2 is involved in
quinacrine efflux). Given that quinacrine is a substrate for Pgp,
we tested whether deletion of the mdr genes (knockout MDR
1a/1b (2/2, 2/2), denoted as MDR0/0) would improve the
pharmacological profile of quinacrine and enhance its in vivo
efficacy.
Here, we report that quinacrine can accumulate in the brains
of orally treated MDR0/0 mice at concentrations exceeding
100 mM. Despite attaining these high concentrations in the
brain, quinacrine failed to extend the survival times of prion-
inoculated MDR0/0 mice. The results suggest that the failure of
quinacrine in vivo cannot be attributed solely to its pharmacoki-
netic properties. Quinacrine treatment transiently reduced PrPSc
levels in the brains of mice, but PrPSc levels recovered during the
course of treatment. Parallel results in cell culture suggest that
continuous quinacrine treatment leads to the selective survival of
drug-resistant prion conformations. However, these resistant
conformations do not stably propagate in the absence of
quinacrine.
Results
Effect of quinacrine treatment on the survival of
prion-inoculated FVB, CD-1 and MDR0/0 mice
We evaluated whether quinacrine treatment would extend the
survival time of prion-infected mice of three genetic backgrounds:
CD1 (wild-type outbred), FVB (wild-type inbred) and MDR0/0. Mice
were inoculated intracerebrally with 30 mL of 1% brain homogenate
containing the Rocky Mountain Laboratory (RML), rodent-
passaged, scrapie prion strain. An oral regimen of 40 mg/kg/day
of quinacrine was initiated at selected time-points [0, 30, 60, 70, 80,
95, and 105 d postinoculation (dpi)] and continued for different time
intervals (10, 20, 30, 50, 60 d, or remaining lifetime of the mouse).
The mice were monitored for neurological dysfunction and sacrificed
upon the onset of prion disease. At least 9 mice were allowed to reach
the endpoint of disease for each arm of the experiment and used to
determine the mean incubation period (Table 1). For some arms,
several mice were sacrificed during the course of the experiment in
order to measure quinacrine uptake, PrPSc levels, and neuropatho-
logic changes (see below). Treated mice will be referred to as S[a-b] or
S[a.], for which ‘‘S’’ is the mouse strain, ‘‘a’’ indicates the initiation
of quinacrine in dpi, ‘‘b’’ indicates the cessation of treatment in dpi,
and ‘‘.’’ indicates lifelong treatment.
We did not observe obvious signs of acute toxicity resulting from
quinacrine treatment in any of the experimental arms. Quinacrine
treatment did not substantially alter the progression of disease
(Table 1). Short-term quinacrine treatment (#30 d) resulted in
statistically significant increases in the incubation periods (P,0.01)
for five experimental arms (Table 1). However, the magnitudes
of these effects were small and all mice developed neurologic
dysfunction. Together, our data indicate that quinacrine is largely
inefficacious in all prion-inoculated mice observed.
Quinacrine accumulation in treated, RML-inoculated FVB
and MDR0/0 mice
We assessed the accumulation of quinacrine in the brains,
kidneys, livers and spleens of FVB[60–90] and MDR0/0[60–90]
mice at 75 and 90 dpi by quantitative LC/MS/MS and
comparison to known standards (Fig. 1). Three mice were
analyzed for each measurement. At 75 dpi, the concentration of
quinacrine in the brains of FVB and MDR0/0 mice were ,1 mM
and ,100 mM, respectively. Quinacrine concentrations were also
greater in all other tissues of MDR0/0 mice compared to FVB
mice. Similar trends were observed in tissues obtained at 90 dpi.
In treated MDR0/0 mice, quinacrine was distributed throughout
the brain and was readily detected in the hippocampus, cortex,
thalamus, cerebellum, and brainstem (Ahn et al., manuscript in
preparation).
Neuropathology of quinacrine-treated, RML-inoculated
MDR0/0 mice
In parallel, we examined neuropathologic changes in prion-
infected MDR0/0[60–90] mice and untreated controls at 75 and
90 dpi (Fig. 2). The brains of infected MDR0/0 mice showed
mild, focal astrocytic gliosis in the thalamus and hippocampus
before quinacrine was administered, which was also observed with
15 d of quinacrine treatment (75 dpi). In comparison, the brains of
untreated mice at 75 dpi showed moderate to severe astrocytic
gliosis in the thalamus and hippocampus, and mild astrocytic
gliosis in the cortex. At 90 dpi, astrocytic gliosis in the brains of
treated and untreated mice showed subtle differences. At the
endpoint of disease, astrocytic gliosis and spongiform degeneration
were similar for both treated and untreated MDR0/0 mice.
Author Summary
Prion diseases belong to the class of neurodegenerative
disorders that include Alzheimer, Parkinson and Hunting-
ton diseases. In each of these disorders, a specific protein
in the brain changes shape and accumulates, leading to
neuronal loss and damage. These diseases are uniformly
fatal after a period of neurodegeneration, dementia and
motor dysfunction. Quinacrine, an antimalarial drug, is able
to eliminate prions from dividing cells in culture, yet is
ineffective in diseased mice and human patients. Here, we
provide an explanation for this failure. Our data indicate
that the administration of quinacrine results in the
proliferation of drug-resistant prions. This insight will
enable us to develop more effective antiprion therapeutics
in the future.
Quinacrine-Resistant Prions
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Together, these data suggest that quinacrine has a slight effect on
neuropathologic changes upon initial administration, but does not
halt widespread neurodegeneration during the course of disease.
PrPSc accumulation in the brains of quinacrine-treated,
RML-inoculated MDR0/0 mice
We analyzed the kinetics of PrPSc accumulation during the
incubation period of MDR0/0[60–90], MDR0/0[0.], and untreated
mice. Two or three animals were sacrificed at 60, 75, 90 and
111 dpi, and the accumulation of protease-resistant PrPSc in the
brain was analyzed by Western immunoblotting (Fig. 3A) and
quantitative ELISA (Fig. 3B) following proteinase K (PK) digestion.
Additionally, PrPSc levels were measured in MDR[60–90] mice at 7
other time-points (64, 69, 75, 78, 81, 84, and 88 dpi). At 60 dpi,
MDR0/0[0.] mice had lower PrPSc levels compared to untreated
controls. At 75 dpi, PrPSc levels were lower in both MDR0/0[0.]
and MDR0/0[60–90] mice compared to untreated controls.
However, this difference was not evident at later time-points even
with continuous quinacrine administration (MDR[0.] mice). In the
absence of quinacrine treatment, PrPSc was readily detectable at
60 dpi. With quinacrine treatment, PrPSc signals were faint but
detectable beginning at 75 dpi, a delay of 15 d compared with no
treatment. In MDR0/0[60–90] mice, PrPSc was abundant before
treatment was initiated (60 dpi), but barely detectable at 69 dpi,
indicating that 9 d of quinacrine treatment reduced PrPSc in the
brain. These data indicate that quinacrine can both delay the
formation and induce the clearance of PrPSc. However, in both
cases, PrPSc eventually accumulated in the brains of quinacrine-
treated animals until they showed neurologic signs of illness. The
transient reduction of PrPSc was not observed in FVB[60–90] mice
(data not shown), indicating that accumulation of quinacrine to high
levels in the brain is required for prion reduction.
Conformational stability and CDI analysis of PrPSc in the
brains of quinacrine-treated, RML-inoculated MDR0/0
mice
While quinacrine did not halt the accumulation of PrPSc in the
brains of infected mice, we asked if whether quinacrine treatment
altered the biochemical characteristics of PrPSc. We prepared 10%
brain homogenates of inoculated, untreated MDR and chronically
treated MDR[0.] mice at the endpoint of disease. We exposed
the samples to increasing concentrations of guanidinium hydro-
chloride (GdnHCl) for 1 h followed by PK digestion, then
Table 1. Incubation periods for prion-infected MDR0/0, FVB and CD1 mice orally treated with 40 mg/kg/day of quinacrine.
Mouse line Treatment initiated (dpi) Treatment duration (d) Incubation period (days6SEM)
MDR0/0 30 60 13564
30 30 14361 *
60 30 12863
60 20 14162 *
60 10 14162 *
60 until death 11562
0 until death 11564
untreated - 12463
FVB 60 30 12861 *
60 until death 11862
untreated - 12162
CD1 105 until death 12162
95 30 12965
95 until death 12963
80 30 11664
80 until death 12162
70 30 14565 *
70 60 13165
70 until death 12162
untreated - 12762
*Statistically significant (P,0.01) prolongation of the incubation period compared to untreated controls. For all experiments, n = 9 mice.
doi:10.1371/journal.ppat.1000673.t001
Figure 1. Accumulation of quinacrine in treated FVB and
MDR0/0 mice. The levels of quinacrine in the brains, kidneys, livers and
spleens of FVB[60–90] (white bars) and MDR0/0[60–90] (black bars) were
measured at 75 and 90 dpi by quantitative LC/MS/MS and comparison
to known standards. The error bars indicate the standard error of the
mean (n= 3).
doi:10.1371/journal.ppat.1000673.g001
Quinacrine-Resistant Prions
PLoS Pathogens | www.plospathogens.org 3 November 2009 | Volume 5 | Issue 11 | e1000673
quantified the levels of protease-resistant PrPSc by ELISA
(Table 2). As an additional control, we also analyzed untreated
brains spiked with 100 mM of quinacrine. PrPSc in the brains of
quinacrine-treated mice was slightly less stable than in the brains
of untreated controls. With 1.3 M GdnHCl, a significantly greater
fraction of quinacrine-exposed PrPSc was denatured compared to
quinacrine-naive PrPSc (n=3; P,0.01). We also analyzed PrPSc in
these brain homogenates using another method, the conforma-
tion-dependent immunoassay (CDI) [19]. This assay measures the
differential ability of PrPSc conformations to bind anti-PrP
Figure 2. Immunohistochemical analyses of brain sections from quinacrine-treated, RML-infected MDR0/0[60–90] mice. Brain sections
were prepared from treated and untreated MDR0/0 mice that were sacrificed 60, 75, and 90 dpi as well as from mice at the endpoint of disease.
Sections were taken from nearly identical regions of the cortex (ctx), hippocampus (hip) and thalamus (thal), then immunostained for the glial
fibrillary acidic protein (GFAP) to visualize astrocytic gliosis. Scale bar represents 50 mm and applies to all panels.
doi:10.1371/journal.ppat.1000673.g002
Figure 3. PrPSc levels in the brains of quinacrine-treated, RML-infected MDR0/0 mice. (A) Western blots show PrPSc levels in the brains of
untreated, MDR0/0[0.], and MDR0/0[60–90] mice that were sacrificed at 60, 75, 90, and 111 dpi. PrPSc accumulation was also probed in infected MDR0/0
[60–90] mice sacrificed at 64, 69, 78, 81, 84, and 88 dpi. Extracts were normalized with respect to the total protein concentration and digested with PK, as
described inMaterials and Methods. Lanes represent brain homogenates of individual mice. Apparent molecular masses based on the migration of protein
standards are shown in kilodaltons. (B) The kinetics of PrPSc accumulation in the brains of untreated MDR0/0 and treated MDR0/0[60–90] mice analyzed
quantitatively by ELISA. Error bars represent the standard error of the mean (n=3).
doi:10.1371/journal.ppat.1000673.g003
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antibodies by measuring the bound ratio between native and
denatured samples following partial purification by phosphotung-
state (PTA). The CDI measurement for PrPSc purified from
quinacrine-treated brains was substantially different from untreated
brains spiked with quinacrine (n=3; P,0.01, Table 2). Together,
these findings suggest that quinacrine exposure altered the physical
properties of PrPSc accumulating in MDR[0.] mice.
Second passages of quinacrine-treated PrPSc
We next determined whether the physically altered, quinacrine-
treated PrPSc could cause disease upon transmission to MDR0/0
mice. Brain homogenates from infected, untreated MDR0/0 and
chronically treated MDR[0.] mice at the endpoint of disease
were inoculated into MDR0/0 mice. The mice were monitored for
neurological dysfunction and sacrificed upon the onset of prion
disease. The mean incubation periods for MDR0/0 mice infected
with untreated and quinacrine-treated inocula were 11263 and
11661 days, respectively (n=8). Analyses of PrPSc in 10% brain
homogenates of these ill mice, using GdnHCl denaturation and
CDI as described above, showed no significant differences in the
stabilities and CDI measurements (Table 3), suggesting that
the physically altered, quinacrine-induced PrPSc is not a stably
propagating strain.
Creation of quinacrine-resistant PrPSc in cultured cells
We next asked if quinacrine-resistant PrPSc could be formed in
cell culture. The re-appearance of drug-resistant PrPSc upon
continuous addition of quinacrine to prion-infected N2a cell lines
(ScN2a) has not been previously observed. Past experiments were
conducted in continuously dividing cultures. Here, we examined
the kinetics of PrPSc clearance in infected cells after differentiation
by exposure to sodium butyrate or dibutyryl cAMP [20,21]
(Fig. 4) to exclude the effect of cell division on prion levels [22].
PrP-overexpressing ScN2a-cl3 cells were plated at 70% confluency
in the presence of 10 mM sodium butyrate or 5 mM dibutyryl
cAMP. The cultures were either left untreated (-Qa), or exposed to
1 mM quinacrine beginning at day 0 (Qa[0.]) or day 4 (Qa[4.]).
In a control experiment, cells were cultured in the absence of
differentiating agents and treated with 1 mM quinacrine beginning
at day 0. After each day, cells were lysed and the relative amount
of PK-resistant PrPSc was measured by ELISA.
In dividing ScN2a-cl3 cultures, quinacrine rapidly cleared PrPSc
and suppressed its accumulation for at least 7 d (Fig. 4A). In
sodium butyrate–treated cultures, PrPSc levels were transiently
reduced by exposure to quinacrine, but increased after 2 d of
treatment (Fig. 4C). The observed PrPSc re-accumulation in
ScN2a-cl3 cells is similar to that observed in treated MDR0/0 mice
and suggests that PrPSc becomes resistant to the effects of
quinacrine upon continuous treatment. Using similar treatment,
drug resistance does not develop for an alternative antiprion
compound, the polyamidoamine (PAMAM) G4 [23] (Fig. 4A, C).
Quinacrine proved similarly ineffective when infected cells were
division-arrested by dibutyryl cAMP (Fig. 4F). This effect of
dibutyryl cAMP is not dependent on activation of the PKA
pathway, as the addition of forskolin does not result in a rebound
in PrPSc levels (Fig. 4A). In differentiated cells exposed to sodium
Table 2. Relative conformational stability and immunospecificity of PrPSc in the brains of MDR0/0 mice continuously treated with
quinacrine compared to untreated controls.
Relative PrPSc (%)
GdnHCl (M) Untreated MDR0/0 Untreated MDR0/0 + 100 mM QA MDR0/0[0.]
0 100.060.0 100.065.0 100.060.0
0.5 92.265.6 85.866.1 88.166.1
1.0 53.868.5 48.663.0 44.362.6
1.3 21.767.1 26.060.7 * 5.961.3 *
1.5 4.561.9 10.260.6 2.363.4
1.7 1.561.7 7.260.4 0.560.9
2.0 0.060.0 0.260.1 0.260.3
CDI (FD/FN) 19.660.1 18.360.1 * 14.060.2 *
At the endpoint of disease, brain homogenates were exposed to the indicated concentrations of GdnHCl for 1 h, then to 50 mg/mL of PK for 1 h at 37uC. As an additional
control, 100 mM quinacrine was added to untreated brain homogenates to mimic the quinacrine content of the treated brain homogenate. The levels of protease-resistant
PrPSc were quantitatively measured by ELISA and normalized to 0 M GdnHCl. CDI measurements are the ratio of ELISA signals from PTA-precipitated native and denatured
PrPSc as described in Materials and Methods. Values are mean percentages 6 standard error (n = 3). * P,0.01.
doi:10.1371/journal.ppat.1000673.t002
Table 3. Relative conformational stability and
immunospecificity of PrPSc in the brains of MDR0/0 mice after
inoculation with untreated and MDR0/0[0.] homogenates.
Relative PrPSc (%)
GdnHCl (M)
Untreated MDR0/0
inoculum MDR0/0[0.] inoculum
0 100.065.0 100.066.0
0.5 100.068.0 102.067.0
1.0 63.864.4 55.364.8
1.3 31.361.1 29.161.9
1.5 12.161.4 15.761.9
1.7 5.660.0 5.061.8
2.0 0.060.0 0.260.1
CDI (FD/FN) 19.560.1 18.560.1
At the endpoint of disease, brain homogenates were exposed to the indicated
concentrations of GdnHCl for 1 h, then to 50 mg/mL of PK for 1 h at 37uC. The
levels of protease-resistant PrPSc were quantitatively measured by ELISA and
normalized to 0 M GdnHCl. CDI measurements are the ratio of ELISA signals from
PTA-precipitated native and denatured PrPSc as described in Materials and
Methods. Values are mean percentages 6 standard error (n = 3).
doi:10.1371/journal.ppat.1000673.t003
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butyrate for 4 d prior to quinacrine administration, PrPSc levels
only decreased after exposure to quinacrine, indicating that
observed changes resulted from quinacrine and not from sodium
butyrate exposure (Fig. 4D). PrPSc slowly increased in untreated,
differentiated cells to levels similar to an untreated confluent
culture (Fig. 4B, 4E). Unlike the in vivo experiments, the PrPSc
that accumulated in division-arrested cells after the addition of
quinacrine did not have a significantly altered conformational
stability (data not shown). Thus, PrPSc can become quinacrine-
resistant without a change in conformational stability as detected
by melting of the protein structure with GdnHCl.
Upon addition of sodium butyrate and dibutyryl cAMP, N2a
cells became differentiated and could not be further passaged.
Instead, in an attempt to propagate quinacrine-treated PrPSc, we
tried to infect N2a cells with lysates from treated cells (data not
shown) but were unable to achieve infection. However, lysates
from control untreated, infected cells were able to infect N2a cells.
We also were unsuccessful at infecting N2a cells with homogenate
Figure 4. Effect of quinacrine on PrPSc levels in division-arrested ScN2a-cl3 cells. Prion-infected ScN2a-cl3 cells were either cultured
normally (–NaBut, panel A), or in the presence of 10 mM sodium butyrate (+NaBut, panels B–D) or 5 mM dibutyryl cAMP (+dbcAMP, panels E–F) in
order to induce differentiation. (A) Dividing cells were treated with 10 mg/mL PAMAM (open squares) or 1 mM quinacrine beginning at day 0
(+Qa[0.]) in the presence (open circles) or absence (filled circles) of 1 mM forskolin. Sodium butyrate–treated cells were (B) left untreated, (C)
incubated with 10 mg/mL PAMAM or 1 mM quinacrine beginning at day 0, or (D) treated with 1 mM quinacrine after splitting on day 4 (+Qa[4.]).
Dibutyryl cAMP–treated cells were (E) left untreated or (F) incubated with 1 mM quinacrine beginning at day 0. Cells were fed with media and
compounds (as required by the experiment) every 2 d. Every day, cells were harvested, lysed, digested with PK and the relative PrPSc levels were
measured by ELISA. The dashed lines represent the relative level of PrPSc in a fully confluent ScN2a-cl3 culture. The error bars represent the standard
error of the mean of three independent experiments.
doi:10.1371/journal.ppat.1000673.g004
Quinacrine-Resistant Prions
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from the brains of quinacrine-treated mice (data not shown). The
difference in infectivity between treated and untreated samples
might indicate a conformational change in PrPSc induced by
quinacrine. However, given that infection of cell lines with prions
is a stochastic phenomenon, we cannot rule out the possibility that
the difference in infectivity was caused by chance.
Discussion
Quinacrine is a potent antiprion drug in culture but has failed to
slow the course of disease in CJD patients and experimental mouse
models of prion disease. It is unclear whether this translational gap
is due primarily to quinacrine’s pharmacokinetic or pharmacody-
namic properties in vivo. As a minimum requirement for in vivo
efficacy, quinacrine must accumulate in the brain at concentra-
tions that exceed its in vitro effective concentration. In chronically
treated wild-type mice, the highest nontoxic tolerable dose of
quinacrine is 40 mg/kg/day (Ahn et al., manuscript in prepara-
tion). At this dose, quinacrine accumulates in the brains of FVB
mice at a concentration of ,1 mM. In continuously dividing,
ScN2a cells, the EC50 of quinacrine is also ,1 mM [9]. However,
this represents the nominal effective concentration of quinacrine
added to the culture media. When N2a cells are exposed to
quinacrine, the intracellular concentration of quinacrine is
typically 30 to 50 times higher than its extracellular concentration
[15] (Ghaemmaghami et al., unpublished results). Thus, the actual
EC50 of quinacrine at its site of action may be much greater than
its reported EC50 value of 1 mM. We therefore reasoned that the
efficacy of quinacrine in vivo might be improved by increasing its
steady-state accumulation in the brain to levels approaching its
intracellular effective concentration. Because the efflux of
quinacrine from the brain is governed by Pgp, an mdr-associated
protein [14,16], active transport can be inhibited by the deletion of
the mdr1a and mdr1b genes (MDR0/0) or the co-administration of
Pgp inhibitors [18]. Here, we orally administered quinacrine to
MDR0/0 mice and achieved drug levels in the brain that were
nearly two orders of magnitude higher than those in FVB mice.
This level of accumulation far exceeds the intracellular EC50 of
quinacrine in culture. Despite its excess accumulation, quinacrine
again failed to extend the survival time of prion-inoculated mice.
The results indicate that quinacrine’s lack of efficacy in vivo is not
solely due to its pharmacokinetic properties and may represent a
pharmacodynamic failure. The data are consistent with a previous
study reporting that continuous intraventricular administration
into the cerebral ventricle does not improve the efficacy of
quinacrine [24].
A recent study reported a decrease in the expression of
cerebovascular Pgp in a CJD patient, suggesting a possible role
for Pgp in prion pathogenesis [25]. However, we did not observe a
significant difference between the incubation periods of inoculat-
ed, untreated MDR0/0 and wild-type mice. These results suggest
that Pgp alone does not significantly influence the accumulation of
PrPSc.
Kinetic analysis of PrPSc levels following drug administration
provided insight into the basis of quinacrine’s failure in vivo. In the
brains of prion-inoculated MDR0/0 mice, PrPSc levels diminished
upon the initiation of quinacrine treatment, remained low for
several days, but gradually increased despite the continuous
presence of the drug. There are two potential explanations for this
trend: (1) target tissues, such as the brain, alter their responsiveness
to quinacrine or (2) prions become resistant to the actions of the
drug. There is precedence for the former phenomenon. It has been
shown that during chronic administration, various drugs and
steroid hormones lose efficacy by inducing the expression of efflux
transformers and cytochrome P450 [26,27,28]. However, we did
not observe a measurable decrease in brain quinacrine levels
during the course of treatment (Fig. 1; Ahn et al., manuscript in
preparation). Therefore, we propose that chronic quinacrine
treatment resulted in the formation of drug-resistant PrPSc
conformations that survived the initial treatment. A similar linkage
between limited efficacy and the formation of drug-resistant prions
was cited for amyloidophilic compounds [29]. The following two
observations are consistent with this hypothesis. First, we observed
that PrPSc accumulating in the brains of chronically treated mice
had a lower conformational stability compared to that of untreated
controls, suggesting that quinacrine induced a structural change
within the prion population. Second, we were able to induce the
formation of quinacrine-resistant prions in cell culture, indicating
that drug resistance can be induced outside the context of the
central nervous system.
Interestingly, the formation of quinacrine-resistant prions is only
observed in division-arrested cultured cells. The steady-state
concentration of PrPSc in a cell is established by the balance
between its rates of formation and clearance. As has been noted
before [22,30], the apparent clearance rate for PrPSc in a dividing
cell is the sum of the rate of catabolism and the rate of cell division.
Thus, the apparent rate of clearance for a given prion
conformation is likely to be slower in stationary cells compared
to dividing cells. In a dividing cell, the process of cell division
artificially enhances the rate of clearance and prevents the
accumulation of PrPSc. Therefore, the probability that a partially
resistant conformation survives quinacrine treatment is increased
in stationary cells. These observations suggest that conducting
drug screens in stationary cells may be more likely to identify
antiprion compounds that prove effective in vivo.
Increasing evidence shows that prion-infected tissues harbor
multiple, distinct PrPSc conformations [31,32,33,34,35,36]. Thus,
in an infected brain, each prion strain may have a different degree
of susceptibility to the actions of quinacrine. In this context, the
administration of quinacrine could provide selective pressure for
the selection of drug-resistant conformations. Indeed, the PrPSc
rebound observed in this study is reminiscent of the failure of
antiviral drugs caused by selection of drug-resistant variants.
However, unlike resistant viral strains, the quinacrine-resistant
conformation formed here was not able to propagate in the
absence of the drug and thus cannot be considered a stably
propagating strain. In the absence of quinacrine, the initial
physical properties of the prion population are rapidly re-
established. In viral therapy, the administration of drug cocktails,
combining compounds with differing modes of action, reduces the
probability of virologic failure. Ultimately, the co-administration
of multiple antiprion compounds may be required in order to
avoid the formation of resistant prion conformations. Additionally,
targeting PrPC, the endogenous substrate shared by all prion
strains, is likely to identify compounds that have broad specificity
and are uniformly effective against all strains.
Materials and Methods
Materials
Quinacrine dihydrochloride, PAMAM G4, forskolin and
sodium butyrate were purchased from Sigma-Aldrich (St. Louis,
MO). N2a cells were obtained from American Tissue Culture
Collection. Minimal essential medium (MEM) with Earle’s salts;
Dulbecco’s Modified Eagle Medium (DMEM) High Glucose 16
with 4.5 g/L D-glucose and L-glutamine and without sodium
pyruvate; cell dissociation buffer; fetal bovine serum (FBS);
Geneticin (50 mg/mL); penicillin-streptomycin (10,000 units/mL
Quinacrine-Resistant Prions
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and 10,000 mg/mL, respectively); and GlutaMAX were purchased
from Gibco. Dithiothreitol (DTT; 0.5 M 106); 46 loading buffer;
and proteinase K (PK) were purchased from Invitrogen. Complete
protease inhibitor (PI) cocktail tablets were from Roche Diagnos-
tics. Western blotting detection reagents 1 and 2 were from GE
Healthcare. Anti-PrP antibodies Fab D18 [37] and Fab D13
conjugated to horseradish peroxidase (HRP) [38] were prepared as
previously described.
Animals and tissue preparation
All protocols were approved by the University of California
San Francisco Animal Care and Use Committee. Approximately
five-week-old male and female wild-type (FVB and CD1) and
MDR0/0 mice were purchased from Charles River (Wilmington,
MA) and Taconic (Germantown, NY), respectively. Mice were
inoculated intracerebrally with 30 mL of 1% brain homogenate
containing the RML prion strain. Treatment consisted of 40 mg/
kg/day of quinacrine in a chocolate-flavored liquid diet [39]
administered beginning at 0, 30, and 60 dpi for MDR0/0 mice;
60 dpi for FVB mice; and 70, 80, 95, and 105 dpi for CD1 mice.
The initiation of quinacrine treatment varied for each mouse
strain to reflect the relative incubation period of the respective
mouse line.
At 75 and 90 dpi, 2–3 mice were euthanized. The left half-brain
was snap frozen on powdered dry ice for quinacrine extraction and
biochemical analysis; the right half-brain was fixed for pathological
analysis. Brain homogenates (10% w/v) were prepared using a
Precellys 24 homogenizer (Bertin Technologies, Montigny-le-
Bretonneux, France) in pure distilled water (Invitrogen, San
Diego, CA) and were aliquoted and stored at 280uC.
Animals were observed every day for signs of neurologic disease.
Mice were diagnosed with prion disease when they exhibited three
or more of the following neurological symptoms: ataxia, circling,
depression, and blank stare. Upon diagnosis, mice were killed and
their brains collected as described above for analysis.
Measurement of quinacrine concentration in tissues
Quinacrine was extracted from brain samples and its concen-
tration was measured by LC/MS/MS as described previously [14]
(Ahn et al., manuscript in preparation). Briefly, working solution
containing 10 mg/mL of quinacrine was diluted with 10% tissue
homogenates from untreated, control animals to make 500 ml of
1 mg/mL of standard 1 solution for each tissue type. The standard
1 solution was then serially diluted two-fold. Nine standard
solutions (200 ml each) and a blank solution (0 mg/mL) were frozen
at 280uC. A total of 400 ml of acetonitrile containing the internal
standard (50 ng/mL of chlorophenamine) was added to 200 ml of
10% tissue homogenates or standard solutions. The samples were
vortexed vigorously twice for 1 min and centrifuged at 16,000 g
for 5 min. LC/MS/MS system consisted of Shimadzu LC-10 AD
pumps, a Waters Intelligent Sample Processor 717 Plus auto-
sampler, and a Micromass Quattro LC Ultima triple quadruple
tandem mass spectrometer. The mass spectrometer was set to
electrospray ionization in the positive-ion mode. Quinacrine and
its metabolites, O-demethylated quinacrine (M1) and mono-
desethyl quinacrine (M2), were monitored by multiple-reaction
monitoring (MRM) at 400.5.142.2 m/z for QA, 384.5.142.2
m/z for M1, 372.2.114.2 m/z for M2, and 277.2.142.2 m/z for
internal standard (chlorphenamine). The column was a Betasil
C18 column (5064.6 mm) from Hypersil-Keystone and the
mobile phase consisted of CH3OH/H2O/trifluoroacetic acid
(45:55:0.05) with 1 mM ammonium formate. The flow rate was
0.8 mL/min.
Measurement of protease-resistant PrPSc
Ten percent brain homogenates (100 mL) were diluted with
1 mL lysis buffer and digested with 20 ml of 1 mg/mL PK at 37uC
for 1 h. PMSF (final concentration of 1 mM) was added to stop the
digestion. Sample volumes of 200 ml were used for ELISA analysis
and of 800 ml for Western blot analysis.
ELISA plates were prepared as described previously [22].
Triplicate samples (200 mL each) were transferred to a 96-well
PCR plate and 50 ml of 6 M GdnHCl (Pierce, Rockford, IL) was
added to each sample. Samples were heated to 85uC for 15 min
and 5 ml of samples were added onto an ELISA plate containing
245 ml of 1% BSA per well. Samples were incubated at 4uC
overnight. The next day, ELISA plates were washed 3 times with
TBST buffer (10 mM Tris/HCl, pH 8.0; 150 mM NaCl; 0.5%
Tween-20). After washes, 100 ml of D13-HRP antibody in 1%
BSA (1:1000 dilution) was added to each well and plates were
incubated at 37uC for 1 h. Subsequently, plates were washed 7
times with TBST and 100 ml of 2,29-azino-bis(3-ethylbenzthiazo-
line-6-sulfonic acid (ABTS) was added to each well. After
developing for 15 to 20 min, plates were read using a SpectraMax
Plus microplate reader running SoftMaxPro (Molecular Devices,
Sunnyvale, CA). In each plate, standard ladders of recombinant
mouse PrP and uninoculated brain samples were placed as
controls.
For Western blot analysis, PrPSc pellets from 800 ml of PK-
digested samples were collected and resuspended with lysis buffer.
SDS sample running buffer and reducing reagent (Invitrogen)
were added. Samples were heated to 95uC for 5 min and run in
a 4–12% Tris-glycine SDS gel (Invitrogen). The gel was trans-
ferred to PVDF membrane using an iBlot (Invitrogen) and the
membrane was blocked with 5% milk for 30 min. The membranes
were subsequently incubated overnight with D13-HRP antibody
and washed 3 times with TBST for 5 min before developing with
ECL reagent.
Conformational-stability assay
Brain homogenates (10 mL) were incubated with GdnHCl, in a
range of 0 to 2 M, at 22uC for 2 h. The samples were subsequently
diluted with lysis buffer to a final concentration of 0.4 M of
GdnHCl. PK was added at a final concentration of 50 mg/mL
and the samples were incubated at 37uC for 1 h. PMSF (final
concentration of 1 mM) was added to stop PK digestion. The
samples were subsequently analyzed by ELISA as described above.
Conformation-dependent immunoassay
Each sample was divided into two aliquots, precipitated by the
addition of 1% PTA and resuspended in lysis buffer. The first
aliquot was untreated and designated native; the second aliquot
was mixed to a final concentration of 4 M GdnHCI, heated for
20 min at 80uC, and designated denatured. Both samples were
diluted 20-fold with lysis buffer containing protease inhibitors
(5 mM PMSF; aprotinin and leupeptin, 4 g/ml each). Then,
200 ml volumes were loaded on 96-well polystyrene plates that
were previously coated with the mAb D18. The plates were
blocked overnight at 18–22uC in 0.2 M phosphate buffer, pH 7.2,
and then blocked with TBST, pH 7.2, containing 0.25% BSA
(w/v) and 6% Sorbitol (w/v), and 0.03% (w/v) NaN3. The plates
were washed 36 with TBS, pH 7.8, containing 0.05% (v/v) of
Tween 20, then incubated at room temperature for 2 h. HRP-
labeled D13 anti-PrP antibody was added and incubated as
described [33]. The plates were developed by the addition of
ABTS (2,29-azino-di 3-ethylbenzthiazoline-6-sulfonate) after seven
washing steps with TBST (Tris-buffered saline Tween-20) and the
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signals were measured. After normalization, the ratios of antibody
binding to denatured versus native aliquots were calculated.
Pathology
After mice were euthanized, their right half-brains were fixed in
10% formalin for a minimum of 3 d. Fixed brains were processed
and embedded in paraffin, and 8-mm sections were cut from four
representative brain regions: cortex, cerebellum, hippocampus and
thalamus. Slides were deparaffinized and endogenous peroxidases
blocked with 3% H2O2 in methanol for 20 min. The slides were
washed 3 times for 5 min using PBS with 0.1% Tween 20 (PBST)
with 3 buffer changes. The glial fibrillary acidic protein (GFAP)
target antigen does not require retrieval for antibody recognition
(rabbit polyclonal anti-GFAP, Dako). Nonspecific antibody
binding was blocked with 5% normal goat serum (NGS) in PBST
for 30 min, then the slides were incubated with the primary
antibody at 1:1000 in PBST at 4uC overnight. After washing, the
sections were incubated with a biotinylated goat anti-rabbit
secondary antibody (Pierce) at 1:1000 in PBST with 5% NGS
for 1 h at room temperature. After additional washing, the Vector
ABC kit was used per the manufacturer’s instructions. Sections
were washed and developed with the Vector DAB kit for 3 min
and washed again. Tween 20 was not present in the third wash.
The sections were counterstained for 10 s in hematoxylin (Fisher),
taken through graded alcohols to xylene, and coverslipped using
Permount (Fisher). Images were taken at 206 and 406
magnifications using the SpotFlex camera and program on the
Leica DM-IRB microscope.
Time-course experiments of quinacrine treatment in
cultured cells
The PrP-overexpressing N2a-cl3 cell line was created by stably
transfecting N2a cells with the pSPOX.neo vector expressing full-
length mouse PrP under the control of the hCMV promoter with
DOTAP liposomal transfection reagent (Roche). Stably transfected
lines were cloned by serial dilution and 15 individual clones were
assayed for PrP expression level by Western immunoblotting. The
N2a-cl3 clone overexpresses PrP at,66the levels of untransfected
N2a cells. N2a-cl3 cells were infected with RML prions as
previously described [40] and subcloned to produce ScN2a-cl3
cells. ScN2a-cl3 cells were maintained at 37uC in MEM
supplemented with 10% FBS and 1% GlutaMAX (Invitrogen) in
100-mm plates and fed with fresh media every 2 d. Approximately
70% confluent cells were plated and 1 mMquinacrine or 10 mg/mL
PAMAMG4 was added in the presence of 10 mM sodium butyrate
or 5 mM dibutyryl cAMP for stationary conditions. Dividing cells
were plated at 10% confluency in the presence of 1 mM quinacrine,
10 mg/mL PAMAM G4 and/or 1 mM forskolin (and absence of
sodium butyrate or dibutyryl cAMP) and split 1:10 when they
become confluent. At the end of each day for 7 d, cells were washed
with PBS and harvested using cell dissociation buffer (Invitrogen).
Cells were lysed with lysis buffer (100 mM Tris/HCl, pH 8.0;
150 mM NaCl; 0.5% NP-40; 0.5% sodium deoxycholate) and
protein concentrations were measured using a bicinchoninic acid
protein assay kit (Fisher, Rockford, IL). Protein extracts were
normalized to 1 mg/mL total protein with lysis buffer prior to PK
digestion and ELISA analysis.
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